Pneumococcal 15-Valent Conjugate Vaccine Approved for Pediatric Use
For children, Vaxneuvance is administered as a 4-dose series at 2, 4, 6 and 12 through 15 months of age (and at least 2 months after the 3rd dose).
For children, Vaxneuvance is administered as a 4-dose series at 2, 4, 6 and 12 through 15 months of age (and at least 2 months after the 3rd dose).
Researchers evaluated the occurrence of adverse events following COVID-19 vaccination with mRNA- and vector-based vaccines, inactivated vaccines, DNA vaccines, and protein subunit vaccines.
The vaccine candidate contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with an adjuvant.
Priorix is administered as a 2-dose series (each dose is approximately 0.5mL) via subcutaneous injection.
Types of COVID-19 vaccines in the US, including those approved by the FDA under Emergency Use Authorization, as well as other investigational products currently in Phase 3 clinical trials.
As the medical field shifted its priorities to treating COVID-19 at the start of the pandemic, routine immunization was one of the many medical fields to experience disruption. What was the scope of this disruption and what are possible ways to address it?
This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines for children 0-18 years of age.
A catch-up immunization schedule for children 4 months to 18 years of age, including minimum intervals between doses of delayed immunizations.
Researchers evaluated the effect of COVID-19 vaccination on immunologic memory response among patients who were previously infected with COVID-19 and had no detectable antibodies following their diagnosis.
Researchers conducted a study to assess the effect of COVID-19 ring vaccination among individuals residing in areas with increased local transmission of the SARS-CoV-2 Alpha variant.